Inhibition of PKCα Reduces the Ability of Migration of Kidney Cancer Cells but Has No Impact on Cell Apoptosis

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2017 Jun 2

PMID 28565866

Citations 4

Authors

Bo Zhan

Chuize Kong

Zhe Zhang

Xiao Dong

Naiwen Zhang

Affiliations

Soon will be listed here.

Abstract

Kidney cancer is among the most important causes of cancer-associated mortality worldwide. The present study aimed to evaluate protein kinase C α (PKCα) expression in kidney cancer tissues and cell lines, and its significance in apoptosis and migration. Expression of PKCα was analyzed using quantitative polymerase chain reaction and western blotting. In addition, the inhibitor of PKCα (calphostin C and GO6976) was used to treat kidney cancer cells. The ACHN cell line was generated with PKCα-small-interfering RNA (siRNA) and a stable expression of PKCα, in order to facilitate the analysis of apoptosis and migration of PKCα during knockdown and inactivation. Flow cytometry was used to determine the rates of apoptosis. Immunohistochemical staining was used to identify the localization of PKCα in renal clear cell carcinoma and normal sections. PKCα expression in normal tissues was found to be greater than in cancerous tissues. Furthermore, apoptosis was not promoted with PKCα inhibitors or PKCα-siRNA treatment, and a decrease of the migration ability was observed following transfection with PKCα-dominant negative. The results indicated that inhibition of PKCα might not contribute to apoptosis progression in kidney carcinoma.

Citing Articles

CEMIP, a Promising Biomarker That Promotes the Progression and Metastasis of Colorectal and Other Types of Cancer.

Domanegg K, Sleeman J, Schmaus A Cancers (Basel). 2022; 14(20).

PMID: 36291875 PMC: 9600181. DOI: 10.3390/cancers14205093.

Targeting Protein Kinase C for Cancer Therapy.

He S, Li Q, Huang Q, Cheng J Cancers (Basel). 2022; 14(5).

PMID: 35267413 PMC: 8909172. DOI: 10.3390/cancers14051104.

The complexities of PKCα signaling in cancer.

Black A, Black J Adv Biol Regul. 2020; 80:100769.

PMID: 33307285 PMC: 8141086. DOI: 10.1016/j.jbior.2020.100769.

Galectin 3 protects from cisplatin-induced acute kidney injury by promoting TLR-2-dependent activation of IDO1/Kynurenine pathway in renal DCs.

Volarevic V, Markovic B, Gazdic Jankovic M, Djokovic B, Jovicic N, Harrell C Theranostics. 2019; 9(20):5976-6001.

PMID: 31534532 PMC: 6735380. DOI: 10.7150/thno.33959.

References

Fan J, Byron K . Ca2+ signalling in rat vascular smooth muscle cells: a role for protein kinase C at physiological vasoconstrictor concentrations of vasopressin. J Physiol. 2000; 524 Pt 3:821-31. PMC: 2269909. DOI: 10.1111/j.1469-7793.2000.00821.x. View

Masur K, Lang K, Niggemann B, Zanker K, Entschladen F . High PKC alpha and low E-cadherin expression contribute to high migratory activity of colon carcinoma cells. Mol Biol Cell. 2001; 12(7):1973-82. PMC: 55643. DOI: 10.1091/mbc.12.7.1973. View

Aaltonen V, Koivunen J, Laato M, Peltonen J . PKC inhibitor Go6976 induces mitosis and enhances doxorubicin-paclitaxel cytotoxicity in urinary bladder carcinoma cells. Cancer Lett. 2007; 253(1):97-107. DOI: 10.1016/j.canlet.2007.01.011. View

Chow W, Devesa S, Warren J, Fraumeni Jr J . Rising incidence of renal cell cancer in the United States. JAMA. 1999; 281(17):1628-31. DOI: 10.1001/jama.281.17.1628. View

Webster C, Johnston A, Anwer M . Protein kinase Cδ protects against bile acid apoptosis by suppressing proapoptotic JNK and BIM pathways in human and rat hepatocytes. Am J Physiol Gastrointest Liver Physiol. 2014; 307(12):G1207-15. PMC: 4269680. DOI: 10.1152/ajpgi.00165.2014. View

Kent E, Ambs A, Mitchell S, Clauser S, Smith A, Hays R . Health-related quality of life in older adult survivors of selected cancers: data from the SEER-MHOS linkage. Cancer. 2014; 121(5):758-65. PMC: 4546846. DOI: 10.1002/cncr.29119. View

Bailey T, Luan H, Tom E, Bielecki T, Mohapatra B, Ahmad G . A kinase inhibitor screen reveals protein kinase C-dependent endocytic recycling of ErbB2 in breast cancer cells. J Biol Chem. 2014; 289(44):30443-30458. PMC: 4215227. DOI: 10.1074/jbc.M114.608992. View

Zhang H, Zhang D, Zha Z, Hu C . Transcriptional activation of PRMT5 by NF-Y is required for cell growth and negatively regulated by the PKC/c-Fos signaling in prostate cancer cells. Biochim Biophys Acta. 2014; 1839(11):1330-40. PMC: 4252817. DOI: 10.1016/j.bbagrm.2014.09.015. View

Fields A, Murray N . Protein kinase C isozymes as therapeutic targets for treatment of human cancers. Adv Enzyme Regul. 2008; 48:166-78. PMC: 2586109. DOI: 10.1016/j.advenzreg.2007.11.014. View

10.

Tanaka Y, Gavrielides M, Mitsuuchi Y, Fujii T, Kazanietz M . Protein kinase C promotes apoptosis in LNCaP prostate cancer cells through activation of p38 MAPK and inhibition of the Akt survival pathway. J Biol Chem. 2003; 278(36):33753-62. DOI: 10.1074/jbc.M303313200. View

11.

Du H, Ou L, Yang X, Song X, Fan Y, Tan B . A new PKCα/β/TBX3/E-cadherin pathway is involved in PLCε-regulated invasion and migration in human bladder cancer cells. Cell Signal. 2013; 26(3):580-93. DOI: 10.1016/j.cellsig.2013.11.015. View

12.

Zhang L, Cao F, Wang Y, Meng F, Zhang Y, Zhong D . The protein kinase C (PKC) inhibitors combined with chemotherapy in the treatment of advanced non-small cell lung cancer: meta-analysis of randomized controlled trials. Clin Transl Oncol. 2014; 17(5):371-7. DOI: 10.1007/s12094-014-1241-3. View

13.

Chuize K, Yuyan Z, Zhe Z, Tao L, Meng Y, Qi Y . Protein kinase C-alpha is expressed and activated during the development of renal cell carcinoma. Urology. 2010; 76(2):514.e1-5. DOI: 10.1016/j.urology.2010.02.064. View

14.

Varga A, Czifra G, Tallai B, Nemeth T, Kovacs I, Kovacs L . Tumor grade-dependent alterations in the protein kinase C isoform pattern in urinary bladder carcinomas. Eur Urol. 2004; 46(4):462-5. DOI: 10.1016/j.eururo.2004.04.014. View

15.

Langzam L, Koren R, Gal R, Kugel V, Paz A, Farkas A . Patterns of protein kinase C isoenzyme expression in transitional cell carcinoma of bladder. Relation to degree of malignancy. Am J Clin Pathol. 2001; 116(3):377-85. DOI: 10.1309/1VKK-HWH7-YVJN-7UF7. View

16.

Zhao Y, Zhou W, Xue L, Zhang W, Zhan Q . Nicotine activates YAP1 through nAChRs mediated signaling in esophageal squamous cell cancer (ESCC). PLoS One. 2014; 9(3):e90836. PMC: 3951250. DOI: 10.1371/journal.pone.0090836. View

17.

Mole D, Gentilin E, Gagliano T, Tagliati F, Bondanelli M, Pelizzo M . Protein kinase C: a putative new target for the control of human medullary thyroid carcinoma cell proliferation in vitro. Endocrinology. 2012; 153(5):2088-98. DOI: 10.1210/en.2011-1988. View

18.

Hsu Y, Yao J, Chan L, Wu T, Hsu J, Fang Y . Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer. Cancer Res. 2014; 74(17):4822-35. PMC: 4154991. DOI: 10.1158/0008-5472.CAN-14-0584. View

19.

Bergelin N, Lof C, Balthasar S, Kalhori V, Tornquist K . S1P1 and VEGFR-2 form a signaling complex with extracellularly regulated kinase 1/2 and protein kinase C-alpha regulating ML-1 thyroid carcinoma cell migration. Endocrinology. 2010; 151(7):2994-3005. DOI: 10.1210/en.2009-1387. View

20.

NISHIZUKA Y . Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science. 1992; 258(5082):607-14. DOI: 10.1126/science.1411571. View